Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD3 | P35462 | 6/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20799623 | 0.82 | OPRM1 (0.46) | FUCA1OPRM1DRD2DRD3 | |
| SCHEMBL20799617 | 0.82 | OPRM1 (0.46) | FUCA1OPRM1DRD2DRD3 | |
| SCHEMBL22773674 | 0.80 | FUCA1 (0.53) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL29597911 | 0.80 | FUCA1 (0.53) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL62966 | 0.76 | OPRM1 (0.65) | OPRM1DRD2 | |
| SCHEMBL5242542 | 0.76 | FUCA1 (0.64) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL7294420 | 0.76 | CHRM2 (0.45) | OPRM1DRD2DRD3 | |
| SCHEMBL20799614 | 0.76 | GRIN2B (0.50) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| Hydrochloric Acid SCHEMBL1147552 | 0.75 | OPRM1 (0.63) | OPRM1DRD2 | |
| SCHEMBL15325219 | 0.74 | OPRM1 (0.57) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435389-B2 | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 | Krouzon Pharmaccuticals, Inc. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190077792-A1 | Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2 | Krouzon Pharmaceuticals, Inc. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077792-A1 | Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2 | PTPN1, PTPN2, PTPN7 | FUCA1 4345/4885OPRM1 2891/4885DRD2 4732/4885 |
| US-10435389-B2 | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 | PTPN1, PTPN2, PTPN7 | FUCA1 4345/4885OPRM1 2891/4885DRD2 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.